Avoro Capital Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $12M | Sell |
330,000
-500,000
| -60% | -$18.2M | 0.21% | 29 |
|
|
2025
Q1 | $30.1M | Hold |
830,000
| – | – | 0.47% | 27 |
|
|
2024
Q4 | $34.9M | Hold |
830,000
| – | – | 0.49% | 27 |
|
|
2024
Q3 | $46.1M | Hold |
830,000
| – | – | 0.67% | 26 |
|
|
2024
Q2 | $34.1M | Hold |
830,000
| – | – | 0.45% | 32 |
|
|
2024
Q1 | $38.8M | Buy |
830,000
+480,000
| +137% | +$22.4M | 0.45% | 37 |
|
|
2023
Q4 | $16.7M | Sell |
350,000
-1,150,000
| -77% | -$55M | 0.23% | 38 |
|
|
2023
Q3 | $53.5M | Buy |
1,500,000
+750,000
| +100% | +$26.7M | 0.83% | 20 |
|
|
2023
Q2 | $34.6M | Hold |
750,000
| – | – | 0.47% | 26 |
|
|
2023
Q1 | $30.1M | Hold |
750,000
| – | – | 0.45% | 28 |
|
|
2022
Q4 | $34.7M | Hold |
750,000
| – | – | 0.52% | 28 |
|
|
2022
Q3 | $31.1M | Hold |
750,000
| – | – | 0.57% | 26 |
|
|
2022
Q2 | $44.7M | Buy |
750,000
+520,000
| +226% | +$31M | 0.88% | 20 |
|
|
2022
Q1 | $16.7M | Buy |
+230,000
| New | +$16.7M | 0.3% | 35 |
|